SignalCorporate
'Why only cancer drugs?': SC questions Centre on trade margin cap, seeks wider price regulation
Supreme Court questions Centre on cancer drug trade margin cap, seeking wider price regulation.
Context
What happened: The Supreme Court questioned why the Centre's proposed 30 per cent trade margin cap covers only specified cancer drugs, urging wider scrutiny of markups across medicines and medical devices.
Why it matters: The bench pressed for broader price regulation, citing large gaps between procurement prices and MRPs. The Centre argued excessive intervention could disrupt market dynamics and affect medicine availability, saying India already has some of the lowest medicine prices globally.
What changed
The Supreme Court questioned why the Centre's proposed 30 per cent trade margin cap covers only specified cancer drugs, urging wider scrutiny of markups across medicines and medical devices.
Why it matters
The bench pressed for broader price regulation, citing large gaps between procurement prices and MRPs. The Centre argued excessive intervention could disrupt market dynamics and affect medicine availability, saying India already has some of the lowest medicine prices globally.